Texas Federal Judge Dismisses Lanham Act Claims Against Compounding Pharmacy
HOUSTON — Eli Lilly & Co. failed to demonstrate how actions by a compounding pharmacy that sells a compounded version of tirzepatide, a U.S. Food and Drug Administration-approved drug for diabetes...To view the full article, register now.
Already a subscriber? Click here to view full article